Shares of Schrödinger Inc. (SDGR) surged over 7% in pre-market trading on Monday after the computational drug discovery company announced a major collaboration deal with pharmaceutical giant Novartis.
Under the multi-year agreement, Schrödinger will work with Novartis to advance multiple drug development candidates into Novartis's portfolio across various therapeutic areas. Schrödinger will receive an upfront payment of $150 million from Novartis, and is eligible for up to $2.3 billion in additional milestone payments and royalties on future product sales if the collaboration is successful.
The deal also includes an expanded multi-year software licensing agreement that will allow Novartis to deploy Schrödinger's computational modeling and enterprise informatics platform at a significant scale across its global research organization. This expanded access to Schrödinger's AI-driven drug discovery technologies is aimed at accelerating Novartis's drug development efforts.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.